Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.

von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A.

Br J Clin Pharmacol. 2006 Nov;62(5):552-9.

2.

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB.

AIDS. 1999 Mar 11;13(4):479-86.

PMID:
10197376
3.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
4.

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.

Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ.

AIDS. 1998 Jul 9;12(10):1163-7.

PMID:
9677165
5.

Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Kredo T, Mauff K, Van der Walt JS, Wiesner L, Maartens G, Cohen K, Smith P, Barnes KI.

Antimicrob Agents Chemother. 2011 Dec;55(12):5616-23. doi: 10.1128/AAC.05265-11.

6.

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.

von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, Staszewski S, Kurowski M, Harder S, Haberl A.

Antivir Ther. 2008;13(8):1039-46.

PMID:
19195329
7.

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.

Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL.

J Infect Dis. 1998 Aug;178(2):368-74.

8.

Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.

Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, Guaraldi G, Vanzini C, Molinari A, degli Antoni A, Regazzi M.

Br J Clin Pharmacol. 2006 Sep;62(3):309-15.

9.

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.

Eur J Clin Pharmacol. 2007 Oct;63(10):935-40.

PMID:
17665183
10.

Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.

Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL.

Pediatr Infect Dis J. 2001 Aug;20(8):803-5.

PMID:
11734746
11.

Pharmacokinetics of antiretrovirals in pregnant women.

Mirochnick M, Capparelli E.

Clin Pharmacokinet. 2004;43(15):1071-87. Review.

PMID:
15568888
12.

Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.

Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E, Bouazza N, Foissac F, Chappuy H, Urien S, Tréluyer JM.

Antimicrob Agents Chemother. 2012 Feb;56(2):857-62. doi: 10.1128/AAC.05244-11.

13.

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.

Battegay M, Arasteh K, Plettenberg A, Bogner JR, Livrozet JM, Witt MD, Mossdorf E, Yong CL, Zhang W, Macha S, Berger F, Stern J, Robinson P, Quinson AM.

Clin Ther. 2011 Sep;33(9):1308-20. doi: 10.1016/j.clinthera.2011.08.003.

PMID:
21872931
14.

Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Flaherty JP, Boffito M, Namakula R, Ryan M, Nakabiito C, Back DJ, Khoo S, Merry C, Scarsi KK.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):345-50. doi: 10.1097/QAI.0b013e3181e9871b.

15.

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.

Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH.

Clin Pharmacol Ther. 2005 Aug;78(2):132-42.

PMID:
16084848
16.

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.

von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.

J Antimicrob Chemother. 2008 Sep;62(3):579-82. doi: 10.1093/jac/dkn204.

17.

Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

Calza L, Manfredi R, Trapani F, Salvadori C, Colangeli V, Borderi M, Grossi G, Motta R, Viale P.

Scand J Infect Dis. 2012 May;44(5):381-7. doi: 10.3109/00365548.2011.642306.

PMID:
22263609
18.

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A.

J Infect Dis. 1999 May;179(5):1116-23.

19.

Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.

Haberl A, Moesch M, Nisius G, Stephan C, Bickel M, Khaykin P, Kurowski M, Brodt R, von Hentig N.

Eur J Clin Pharmacol. 2010 Apr;66(4):375-81. doi: 10.1007/s00228-009-0767-8.

PMID:
20033681
20.

Pharmacokinetics of tenofovir during pregnancy and postpartum.

Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M; International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s Team..

HIV Med. 2015 Sep;16(8):502-11. doi: 10.1111/hiv.12252.

Items per page

Supplemental Content

Support Center